(MENAFN- EIN Presswire) market-scope.jpeg" width="300" height="88" alt="Heplisav B market Report 2025 : Market Size, Trends, And Global Forecast 2025-2034" style="max ...

EMERYVILLE, Calif. - Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company with a ...

The company’s Heplisav-B vaccine, which is the only two-dose adult Hepatitis B vaccine, reported a significant year-over-year sales increase, reaching the upper end of the guidance for 2024.

HEPLISAV-B achieved preliminary quarterly net product revenue of $71M for the fourth quarter of 2024, an increase of 39% compared to $51M for the fourth quarter of 2023. Q4 revenue consensus $71.71M.

The study, reported Dec. 1 in JAMA, showed that hepatitis B vaccine with a cytosine phosphoguanine adjuvant, known as HepB-CpG, (trade name Heplisav-B) induced protective levels of antibodies in ...

The US FDA has asked Dynavax Technologies Corporation for additional safety data on its investigational adult hepatitis B vaccine, Heplisav. Heplisav combines hepatitis B surface antigen with a ...

Trials with Heplisav were halted last month in response to a serious adverse effect report from a phase 3 trial comparing Heplisav to a marketed hepatitis B vaccine, Engerix-B, sold by ...

"We are excited to announce that HEPLISAV-B has achieved record annual revenue in 2024, reflecting 26% growth year-over-year, and positioning us at the upper tier of our updated guidance range.

An update from Dynavax ( (DVAX) ) is now available. Dynavax announced a 26% year-over-year increase in net product revenue for HEPLISAV-B in 2024, reaching approximately $268 million. The company ...